Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Articles online first > Giornale Italiano di Dermatologia e Venereologia 2020 Oct 09

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Giornale Italiano di Dermatologia e Venereologia 2020 Oct 09

DOI: 10.23736/S0392-0488.20.06623-7

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Efficacy of Certolizumab Pegol in naïve versus multi-treated patients affected by psoriatic arthritis

Annunziata DATTOLA 1 , Laura VOLLONO 1, Maria Vittoria CANNIZZARO 1, Raffaele D. CAPOSIENA CARO 1, Sara MAZZILLI 1, Gennaro MELINO 2, Eleonora CANDI 2, Elena CAMPIONE 1, Luca BIANCHI 1

1 Department of Dermatology, University of Rome "Tor Vergata", Rome, Italy; 2 Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy


PDF


BACKGROUND: The efficacy and safety of Certolizumab Pegol over 52 weeks was compared in two groups of patients: Group 1 comprised patients naïve to biologic treatments; Group 2 comprised patients previously treated with one or more anti-Tumor necrosis factor (TNF)-alpha and/or antiinterleukin (IL) agents.
METHODS: We reported results in 50 patients affected by both mild psoriasis (PsO) and psoriatic arthritis (PsA). Primary endpoint was a reduction from baseline at week 52 of Disease Activity Score (DAS44-ESR) in both groups of patients. Secondary endpoints were a reduction from baseline at week 52 of Psoriasis Area Severity Index (PASI), Visual Analog Scale for Pain (PAIN VAS), ESR, CRP, and Dermatology life quality index (DLQI).
RESULTS: We observed a statistically significant improvement of both cutaneous and rheumatic disease in all patients, with a consistent reduction of DAS44-ESR, PASI, and PAIN VAS from baseline to week 52. DAS44-ESR decreased from 3.9 at BL to 1.5 at W52 (Group 1), and from 3.8 to 1.7 at W52 (Group 2). Mean PASI score decreased from 3.2 at baseline (BL) to 0.4 at W52 (Group 1), and from 5.4 to 0.7 at W52 (Group 2). Mean PAIN-VAS decreased from a value of 73.5 at BL to 2.5 at W52 (Group 1), and from a value of 62.4 at BL to 9.2 at W52 (Group 2). We also found a reduction in ESR, CRP and DLQI values for each time point.
CONCLUSIONS: Our results confirm that CZP can be administered safely and effectively to treat both psoriasis and psoriatic arthritis irrespective of previous treatments with biologic agents.


KEY WORDS: Psoriasis; Certolizumab Pegol; Naïve patients; Multi-treated patients

top of page